LSE:AZNPharmaceuticals
AstraZeneca’s ctDNA Trials Reframe Breast And Liver Cancer Prospects For AZN Investors
AstraZeneca (LSE:AZN) reported landmark Phase III results for camizestrant plus a CDK4/6 inhibitor in HR-positive, HER2-negative advanced breast cancer using a first-of-its-kind ctDNA-guided treatment switch approach in the SERENA-6 trial.
The SERENA-6 study showed sustained and significant progression-free survival benefit when patients were switched early based on ctDNA monitoring.
Separately, EMERALD-3 data showed a statistically significant and clinically meaningful progression-free...